Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295612 | 0.80 | LMNA (0.75) | CA9LMNAHPGDSMN1; SMN2FAAH | |
| SCHEMBL17295616 | 0.80 | LMNA (0.75) | CA9LMNAHPGDSMN1; SMN2FAAH | |
| SCHEMBL19481525 | 0.78 | ALDH1A1 (0.56) | CA9PTP4A3LMNAHPGDSMN1; SMN2 | |
| SCHEMBL17309399 | 0.78 | ALDH1A1 (0.55) | CA9PTP4A3LMNAHPGDSMN1; SMN2 | |
| SCHEMBL17309371 | 0.77 | CA9 (0.72) | CA9LMNAFAAHMEN1KMT2A | |
| SCHEMBL3891738 | 0.77 | PTPN1 (0.59) | CA9LMNAHPGDSMN1; SMN2FAAH | |
| SCHEMBL3891749 | 0.77 | PTPN1 (0.59) | CA9LMNAHPGDSMN1; SMN2FAAH | |
| SCHEMBL3891123 | 0.76 | CA9 (0.56) | CA9LMNAHPGDSMN1; SMN2FAAH | |
| SCHEMBL12013726 | 0.76 | CA9 (0.56) | CA9LMNAHPGDSMN1; SMN2FAAH | |
| SCHEMBL3891119 | 0.76 | CA9 (0.56) | CA9LMNAHPGDSMN1; SMN2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148541-B1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIV BERN (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10300048-B2 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | UNIVERSITAT BERN (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-10-19 | — | — | US | disclosed |
| EP-2952188-A1 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | Universität Bern (CH) | 2015-12-09 | — | — | EP | disclosed |
| WO-2015181336-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | Universität Bern (CH) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300048-B2 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | SLC18A2, AANAT, CNR2 | CA9 4726/4885PTP4A3 1617/4885LMNA 3797/4885 |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | SLC18A2, AANAT, CNR2 | CA9 4726/4885PTP4A3 1617/4885LMNA 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.